Why These 2 Biotechs Are Soaring
The following video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson and industrials editor/analyst Isaac Pino discuss topics across the investing world.
In this video, David and Isaac discuss two biotechs that have recently seen shares soar. Regeneron has been on a tear and seemingly can't raise Eylea guidance fast enough. Amarin is well off 52-week highs, but bad news for a competitor is good news for Amarin. Can both stocks keep the runs going, or should investors stay on the sidelines post-pop? Watch and find out.
Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report: "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.
At the time this article was published David Williamson owns shares of Amarin (ADR). Isaac Pino has no positions in the stocks mentioned above. The Motley Fool owns shares of GlaxoSmithKline.Motley Fool newsletter services recommendGlaxoSmithKline. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.